Peptilotbeta

Latest research

The peptide literature, summarized and graded.

Every paper distilled to a plain-language summary with an honest evidence grade — from strong human trials to animal-only signals. 1 papers indexed and counting.

Ask the literature →
Sourceallpaperstrialsyoutube
Evidenceallreviewinsufficientlimited humananimal onlymoderate humanin vitro onlystrong humanpreclinical mixed
CompoundGLP-1semaglutidetirzepatideretatrutidethymosin beta-4BPC-157TB-500cagrilintidesermorelinsurvodutideGHK-CumazdutidePT-141melanotan
Filtered by #mazdutide · clear
🧪 TrialInsufficient

Mazdutide for Adults With Prediabetes: A Randomized, Double-Blind, Placebo-Controlled Trial (DREAM-PRE)

Registered Phase 4 interventional trial (not yet recruiting). Prediabetes affects millions of adults worldwide and carries a high risk of progression to type 2 diabetes. Mazdutide is a once-weekly injectable drug that activates both GLP-1 and glucagon receptors, lowering blood sugar and body weight simultaneously. This study (DREAM-PRE) tests whether mazdutide can help adults with prediabetes return to normal blood sugar levels. Approximately 150 adults aged 18-75 years with prediabetes and BMI ≥22 kg/m² will be randomly assigned in equal numbers to one of three groups: mazdutide 4 mg once wee

#GLP-1#mazdutide
ClinicalTrials.gov · Jun 2026View trial ↗